Department of Clinical Pharmacy, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210002, China.
Department of Clinical Pharmacy, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210002, China; Department of Clinical Pharmacy, Nanjing Jinling Hospital, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Biosens Bioelectron. 2023 Oct 1;237:115456. doi: 10.1016/j.bios.2023.115456. Epub 2023 Jun 13.
Recombinase polymerase amplification (RPA) running at 37-42 °C is fast, efficient and less-implemented; however, the existing technologies of nucleic acid testing based on RPA have some limitations in specificity of single-base recognition and multiplexing capability. Herein, we report a highly specific and multiplex RPA-based nucleic acid detection platform by combining flap endonuclease 1 (FEN1)-catalysed invasive reactions with RPA, termed as FEN1-aided RPA (FARPA). The optimal conditions enable RPA and FEN1-based fluorescence detection to occur automatically and sequentially within a 25-min turnaround time and FARPA exhibits sensitivity to 5 target molecules. Due to the ability of invasive reactions in discriminating single-base variation, this one-pot FARPA is much more specific than the Exo probe-based or CRISPR-based RPA methods. Using a universal primer pair derived from tags in reverse transcription primers, multiplex FARPA was successfully demonstrated by the 3-plex assay for the detection of SARS-CoV-2 pathogen (the ORF1ab, the N gene, and the human RNase P gene as the internal control), the 2-plex assay for the discrimination of SARS-CoV-2 wild-type from variants (Alpha, Beta, Epsilon, Delta, or Omicrons), and the 4-plex assay for the screening of arboviruses (zika virus, tick-borne encephalitis virus, yellow fever virus, and chikungunya virus). We have validated multiplex FARPA with 103 nasopharyngeal swabs for SARS-CoV-2 detection. The results showed a 100% agreement with RT-qPCR assays. Moreover, a hand-held FARPA analyser was constructed for the visualized FARPA due to the switch-like endpoint read-out. This FARPA is very suitable for pathogen screening and discrimination of viral variants, greatly facilitating point-of-care diagnostics.
37-42°C 下运行的重组酶聚合酶扩增(RPA)快速、高效且实施要求较低;然而,基于 RPA 的核酸检测现有技术在单碱基识别的特异性和多重化能力方面存在一些局限性。在此,我们通过将 flap endonuclease 1(FEN1)催化的侵入反应与 RPA 相结合,报道了一种基于 RPA 的高特异性和多重核酸检测平台,称为 FEN1 辅助 RPA(FARPA)。优化条件使 RPA 和基于 FEN1 的荧光检测能够在 25 分钟的周转时间内自动且顺序发生,并且 FARPA 对 5 个靶标分子具有敏感性。由于侵入反应具有区分单碱基变异的能力,因此这种一锅法 FARPA 比基于 Exo 探针或 CRISPR 的 RPA 方法具有更高的特异性。使用从逆转录引物标签衍生的通用引物对,通过用于检测 SARS-CoV-2 病原体的 3 重 FARPA(ORF1ab、N 基因和作为内参的人 RNase P 基因)、用于区分 SARS-CoV-2 野生型和变体(Alpha、Beta、Epsilon、Delta 或 Omicron)的 2 重 FARPA,以及用于筛查虫媒病毒(寨卡病毒、蜱传脑炎病毒、黄热病毒和基孔肯雅病毒)的 4 重 FARPA 成功地证明了多重 FARPA 的可行性。我们使用 103 个鼻咽拭子对 SARS-CoV-2 进行了多重 FARPA 验证。结果与 RT-qPCR 检测结果完全一致。此外,由于具有开关样终点读取功能,构建了一种用于可视化 FARPA 的手持式 FARPA 分析仪。由于 FARPA 具有开关样终点读取功能,因此该 FARPA 非常适合用于病原体筛选和病毒变体的区分,极大地促进了即时诊断。